Abstract

Guidelines acknowledge the emerging role of high-sensitivity cardiac troponin (hs-cTnl) for risk stratification and the early rule-out of myocardial infarction, but multiple thresholds have been described. We evaluate the safety and effectiveness of risk stratification thresholds in patients with suspected acute coronary syndrome. Consecutive patients with suspected acute coronary syndrome (n=48 282) were enrolled in a multicenter trial across 10 hospitals in Scotland. In a prespecified secondary and observational analysis, we compared the performance of the limit of detection (<2 ng/L) and an optimized risk stratification threshold (<5 ng/L) using the Abbott high-sensitivity troponin I assay. Patients with myocardial injury at presentation, with ≤2 hours of symptoms or with ST-segment elevation myocardial infarction were excluded. The negative predictive value was determined in all patients and in subgroups for a primary outcome of myocardial infarction or cardiac death within 30 days. The secondary outcome was myocardial infarction or cardiac death at 12 months, with risk modeled using logistic regression adjusted for age and sex. In total, 32 837 consecutive patients (61±17 years, 47% female) were included, of whom 23 260 (71%) and 12,716 (39%) had hs-cTnl concentrations of <5 ng/L and <2 ng/L at presentation. The negative predictive value for the primary outcome was 99.8% (95% CI, 99.7%-99.8%) and 99.9% (95% CI, 99.8%-99.9%) in those with hs-cTnl concentrations of <5 ng/L and <2 ng/L, respectively. At both thresholds, the negative predictive value was consistent in men and women and across all age groups, although the proportion of patients identified as low risk fell with increasing age. Compared with patients with hs-cTnl concentrations of ≥5 ng/L but <99th centile, the risk of myocardial infarction or cardiac death at 12 months was 77% lower in those <5 ng/L (5.3% vs 0.7%; adjusted odds ratio, 0.23 [95% CI, 0.19-0.28]) and 80% lower in those <2 ng/L (5.3% vs 0.3%; adjusted odds ratio, 0.20 [95% CI, 0.14-0.29]). Use of risk stratification thresholds for hs-cTnl identify patients with suspected acute coronary syndrome and at least 2 hours of symptoms as low risk at presentation irrespective of age and sex. URL: https://www.clinicaltrials.gov. Unique identifier: NCT01852123.

Highlights

  • IntroductionThe limit of detection has been proposed,[11,12,13] but assay performance at this level is variable, potentially reducing the consistency and effectiveness of this approach.[14,15,16,17] We previously defined the optimal risk stratification threshold as the highest troponin concentration that gave a negative predictive value for myocardial infarction or cardiac death at 30 days of at least 99.5%,6 to maximise the number of patients identified as low-risk whilst maintaining safety

  • In 32,837 consecutive patients with suspected acute coronary syndrome and at least 2 hours of symptoms, we evaluated the performance of two risk stratification thresholds for a high-sensitivity cardiac troponin I assay

  • Proportion and characteristics of patients identified by risk stratification thresholds In our analysis population, 23,260 (71%) had a cardiac troponin concentration below 5 ng/L, and 9,577 (29%) were between 5 ng/L and the 99th centile

Read more

Summary

Introduction

The limit of detection has been proposed,[11,12,13] but assay performance at this level is variable, potentially reducing the consistency and effectiveness of this approach.[14,15,16,17] We previously defined the optimal risk stratification threshold as the highest troponin concentration that gave a negative predictive value for myocardial infarction or cardiac death at 30 days of at least 99.5%,6 to maximise the number of patients identified as low-risk whilst maintaining safety. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01852123

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.